









Markets
/
Stocks
/
nasdaq-kpti
/

Karyopharm Therapeutics Inc

KPTI

5.360USD

-0.290-5.13%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

46.64MMarket Cap

LossP/E TTM



Karyopharm Therapeutics Inc

5.360

-0.290-5.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Karyopharm Therapeutics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Karyopharm Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

104 / 159

Overall Ranking

266 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

13.833

Target Price

+144.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Karyopharm Therapeutics Inc Highlights

StrengthsRisks

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Overvalued

The company’s latest PE is -0.37, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.64M shares, decreasing 12.73% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 65.81K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 8.06, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.06

Change



Financials

5.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.88

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.59

Key Metrics

Free cash flow

No Data

Karyopharm Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.08, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.37, which is -30.32% below the recent high of -0.25 and -602.60% above the recent low of -2.57.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.29, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Karyopharm Therapeutics Inc is 13.50, with a high of 21.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

13.833

Target Price

+144.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Karyopharm Therapeutics Inc

KPTI

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 4.76, which is lower than the Pharmaceuticals industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 6.29 and the support level at 4.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.79

Change

-1.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.147

Sell

RSI(14)

38.514

Neutral

STOCH(KDJ)(9,3,3)

13.497

Sell

ATR(14)

0.455

High Vlolatility

CCI(14)

-181.502

Sell

Williams %R

98.365

Oversold

TRIX(12,20)

-0.126

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.768

Sell

MA10

6.020

Sell

MA20

5.993

Sell

MA50

6.286

Sell

MA100

5.453

Sell

MA200

5.941

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 29.19%, representing a quarter-over-quarter decrease of 40.01%. The largest institutional shareholder is The Vanguard, holding a total of 408.22K shares, representing 2.56% of shares outstanding, with 57.74% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

J. Wood Capital Advisors LLC

458.13K

T. Rowe Price Investment Management, Inc.

728.77K

+421.87%

J.P. Morgan Securities LLC

256.44K

+73.95%

Adage Capital Management, L.P.

421.32K

The Vanguard Group, Inc.

Star Investors

518.27K

+1.56%

Eversept Partners, LP

257.15K

Citadel Advisors LLC

206.78K

-0.06%

Palo Alto Investors LP

187.91K

-42.01%

BlackRock Institutional Trust Company, N.A.

184.85K

-1.68%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.76, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.